Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Results and rational behind breakthrough therapy-designated E-selectin antagonist for AML

Daniel DeAngelo • 10 Dec 2017
ASH 2017
Acute Myeloid Leukemia Leukemia Uproleselan

The binding of E-selectin to leukemic cells has been shown to promote cell survival and chemotherapy resistance in acute myeloid leukemia (AML). In this interview, Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses a novel therapeutic that is antagonistic towards E-selectin, GMI-1271. Dr DeAngelo discusses the rationale behind the mechanism of action of this drug and the results of the trial investigating this agent (NCT02306291), which he presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Daniel DeAngelo

Bezuclastinib in advanced systemic mastocytosis: the APEX trial
2:34
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
Daniel DeAngelo • 11 Jun 2026
The efficacy and safety of uproleselan plus chemotherapy versus chemotherapy alone in R/R AML
1:14
The efficacy and safety of uproleselan plus chemotherapy versus chemotherapy alone in R/R AML
Daniel DeAngelo • 6 Dec 2024
Dose optimization of inotuzumab ozogamicin in adult patients with R/R ALL
0:42
Dose optimization of inotuzumab ozogamicin in adult patients with R/R ALL
Daniel DeAngelo • 6 Dec 2024
Dose optimization portion of the APEX trial investigating bezuclastinib in patients with AdvSM
0:53
Dose optimization portion of the APEX trial investigating bezuclastinib in patients with AdvSM
Daniel DeAngelo • 6 Dec 2024

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals